Page last updated: 2024-10-26

donepezil and Kidney Stones

donepezil has been researched along with Kidney Stones in 1 studies

Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.

Research Excerpts

ExcerptRelevanceReference
"Sulfasalazine is an anti-inflammatory agent commonly used in the treatment of autoimmune conditions such as inflammatory bowel disease and rheumatoid arthritis."5.46Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury. ( Durando, M; Kim, JS; Tiu, H, 2017)
"Sulfasalazine is an anti-inflammatory agent commonly used in the treatment of autoimmune conditions such as inflammatory bowel disease and rheumatoid arthritis."1.46Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury. ( Durando, M; Kim, JS; Tiu, H, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Durando, M1
Tiu, H1
Kim, JS1

Other Studies

1 other study available for donepezil and Kidney Stones

ArticleYear
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:6

    Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa;

2017